🇺🇸 cisatracurium besilate in United States

185 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaphylactic Shock — 46 reports (24.86%)
  2. Hypotension — 29 reports (15.68%)
  3. Anaphylactic Reaction — 22 reports (11.89%)
  4. Cardiac Arrest — 15 reports (8.11%)
  5. Hypoxia — 14 reports (7.57%)
  6. Klebsiella Infection — 13 reports (7.03%)
  7. Toxic Epidermal Necrolysis — 13 reports (7.03%)
  8. Bronchospasm — 11 reports (5.95%)
  9. Erythema — 11 reports (5.95%)
  10. Metabolic Acidosis — 11 reports (5.95%)

Source database →

cisatracurium besilate in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is cisatracurium besilate approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for cisatracurium besilate in United States?

University Hospital, Clermont-Ferrand is the originator. The local marketing authorisation holder may differ — check the official source linked above.